Influence of cyclophosphamide (Endoxan) and azimexone (BM 12.531), 2-[2-Cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, on the bone marrow cells of mice.

Summary The alkylating compound cyclophosphamide reduces the bone marrow cellularity andthe number of leucocytes in peripheral blood and the thymidine incorporation in bone marrow cells (75 mg/kg i.p.). After 3 hrs a significant increase in the thymidine incorporation was found. 25 hrs after administration there was a quick rebound to values above the control values. Azimexone at a dose of 50 mg/kg p.o. shows no effect on the cellularity of the bone marrow or on the thymidine-incorporation.

[1]  D. Berd,et al.  CRITICAL REVIEW OF PREVIOUSLY REPORTED CLINICAL TRIALS OF CANCER IMMUNOTHERAPY WITH NON‐SPECIFIC IMMUNOSTIMULANTS * , 1976, Annals of the New York Academy of Sciences.

[2]  U. Bicker.  N-(2-cyanethylene-)urea--an asparagine analogous cytostatic compound? , 1975, Experimentelle Pathologie.

[3]  W. Gassel,et al.  Influence of the immunomodulating compound BM 12.531 (azimexone) on radioresistance and granulopoietic colony forming units in mice. , 1981, Experimental pathology.

[4]  U. Bicker,et al.  Carcinostatic action of 2-cyanaziridines against a sarcoma in rats. , 1975, Experimentelle Pathologie.

[5]  E. Hersh,et al.  IMMUNOTHERAPY OF HUMAN SOLID TUMORS WITH BACILLUS CALMETTE‐GUÉRIN: PROLONGATION OF DISEASE‐FREE INTERVAL AND SURVIVAL IN MALIGNANT MELANOMA, BREAST, AND COLORECTAL CANCER * , 1976, Annals of the New York Academy of Sciences.

[6]  M. Chirigos,et al.  The immunomodulatory effect on BM 12.531 (azimexon) on normal or tumored mice: in vitro and in vivo studies. , 1980, Journal of immunopharmacology.

[7]  U. Bicker.  Immunomodulating effects of BM 12.531 in animals and tolerance in man. , 1978, Cancer treatment reports.

[8]  E. Boesen,et al.  Cytotoxic drugs in the treatment of cancer , 1969 .

[9]  G. Mathé.  Cancer active immunotherapy. Immunoprophylaxis and immunorestoration. An introduction. , 1976, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[10]  M. Ardenne,et al.  [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic , 1975, Arzneimittel-Forschung.

[11]  U. Bicker,et al.  Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)]-propane BM 12 531. , 1978, Experimentelle Pathologie.